CLVLY

Clinuvel Pharmaceuticals Limited [CLVLY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CLVLY Stock Summary

Top 10 Correlated Stocks

CLVLY

In the News

CLVLY Financial details

Company Rating
-
Market Cap
490.24M
Income
56.55M
Revenue
151.67M
Book val./share
-
Cash/share
-
Dividend
0.03
Dividend %
0.2%
Employees
-
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
26.79
Forward P/E
-
PEG
1.56
P/S
10.13
P/B
4.98
P/C
-
P/FCF
22.11
Quick Ratio
7.02
Current Ratio
7.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.14
EPS next Y
-
EPS next Q
-
EPS this Y
47.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
10.29%
Revenue last 5Y
20.33%
Revenue Q/Q
-34.12%
EPS Q/Q
-43.59%
-
-
-
-
SMA20
0.94%
SMA50
-3.46%
SMA100
-22.61%
Inst Own
-
Inst Trans
-
ROA
16%
ROE
22%
ROC
0.26%
Gross Margin
90%
Oper. Margin
56%
Profit Margin
39%
Payout
6%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.54-13.97
52W High
-40.31%
52W Low
-3%
RSI
54.45
Rel Volume
0.08
Avg Volume
3.74K
Volume
306
Perf Week
8.23%
Perf Month
3.88%
Perf Quarter
-21.62%
Perf Half Y
-17.71%
-
-
-
-
Beta
0.744
-
-
Volatility
0.37%, 0.26%
Prev Close
1.04%
Price
7.76
Change
-3.72%

CLVLY Financial Performance

CLVLY Dividend History

CLVLY Frequently Asked Questions

What is Clinuvel Pharmaceuticals Limited stock symbol ?

Clinuvel Pharmaceuticals Limited is a AU stock , located in Melbourne of Vic and trading under the symbol CLVLY

What is Clinuvel Pharmaceuticals Limited stock quote today ?

Clinuvel Pharmaceuticals Limited stock price is $7.76 today.

Is Clinuvel Pharmaceuticals Limited stock public?

Yes, Clinuvel Pharmaceuticals Limited is a publicly traded company.

Something similar

Top by Market Cap
3V64.DE
GOOGL
TSLA
EMBASSY.NS
0YXG.L
Same Sector
MAXHEALTH.NS
002433.SZ
AEZS.TO
PHG
AALR3.SA
Top Correlated Stocks
COFFEEDAY.NS
ETCMY
Similar Market Cap
JPDEX
MASTX
STET
MLCVG.PA
OSBC

Company Profile

Healthcare Biotechnology
  • Volume Average 3.74K
  • Market Capitalization 490.24M
  • CEO Dr. Philippe Jacques Wolgen M.B.A., M.D.
  • Headquarters Melbourne,VIC,AU
  • IPO Date 2008-01-30
  • Website https://www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.